
    
      The secondary objectives of this study are to evaluate the following at 3 months, 6 months
      and 12 months after TAVI in both groups:

        1. Mortality (all causes).

        2. Cardiovascular mortality.

        3. The occurrence of myocardial infarction.

        4. The occurrence of stroke.

        5. The occurrence of valve thrombosis.

        6. The occurrence of major bleeding (BARC ≥ 3).

        7. The occurrence of minor bleeding (2 ≤ BARC <3).

        8. Treatment compliance.
    
  